Warburg Pincus and Mubadala Acquire Pharma Intelligence from Informa
Posted on 02/10/2022
Private equity firm Warburg Pincus announced the acquisition of Pharma Intelligence, a provider of specialist intelligence, data, and software for clinical trials, drug development, and regulatory compliance, from Informa PLC (LSE:INF.L). Mubadala Investment Company joins Warburg Pincus in the investment. The investors plan to extend the company’s position in the pharmaceutical data and analytics market, investing in the creation of innovative products for its customers. Informa will retain 15% ownership in the company.
Informa has agreed to divest Pharma Intelligence, the largest business within its Informa Intelligence division, to Warburg Pincus for £1.9 billion, while separately commencing a share buyback. In 2020, this business accounted for approximately 40% of Informa Intelligence reported divisional revenues of £305 million.
Following completion and separation of Pharma intelligence, Informa will proceed with the next process in its GAP II divestment plans, focusing on its Financial Intelligence business comprising EPFR Global, IGM and Zephyr but excluding the retail banking joint venture, Curinos.
Pharma Intelligence holds a position in the clinical trial intelligence space, providing insights on patient enrollment and demographics, trial progress, individual trial sites and investigators for more than 375,000 clinical trials across 180 countries. The company’s solutions are used by 3,000 pharmaceutical companies and CROs in their clinical trial design, commercial strategy, and regulatory compliance processes to maximize the likelihood of success of introducing products to market. The acquisition includes Informa’s full portfolio of specialist brands which includes the Citeline suite of products, Trialtrove, Sitetrove, Pharmaprojects and Citeline branded products, as well as Biomedtracker, Clinerion, Datamonitor Healthcare, Pink Sheet, Scrip, Skipta, and TrialScope.
The acquisition is expected to complete within the first half of 2022, subject to any relevant regulatory clearances.
